RxDoctor Payments Data

Noah Scherrer, MD

Vascular Surgery · Louisville, KYNPI 1740423896

Payments from drug & device makers

What this record shows

W. L. Gore & Associates, Inc. accounts for 66.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $2,907 and has fallen 61.0% since, to $1,135 in 2025. That places this record below the midpoint for vascular surgery clinicians in KY, where the typical reported total is $9,151.

$7,599in general payments, 2019–2025

Across 115 payments — averaging $66.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$5K
  • Boston Scientific$960
  • Terumo Medical Corporation$240
  • Sanara Medtech Inc.$198
  • Endologix LLC$171
  • Bolton Medical Inc$155
  • plus $862 from 21 others

What the payments were for

  • Travel & lodging$3,61548%
  • Food & beverage$3,98452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,599 in reported general payments places this provider in the 40th percentile of 72 vascular surgery providers in Kentucky.

See all vascular surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$351,730
Medicare patients
1,798
Services billed
3,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$58,799
XareltoRivaroxaban19$18,108
Cilostazol92$1,368
ClopidogrelClopidogrel Bisulfate154$1,079
Atorvastatin Calcium99$526
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$140
Pravastatin Sodium19$101
Oxycodone Hcl18$50
Pantoprazole Sodium11$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$58,79988 claims
Johnson & JohnsonXarelto$13$18,10819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 72 vascular surgery providers in Kentucky.

Other vascular surgery in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →